• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Should direct thrombin inhibitors replace warfarin for prophylaxis of thromboembolism in canadians with atrial fibrillation?

出版信息

Can J Hosp Pharm. 2012 Sep;65(5):401-5. doi: 10.4212/cjhp.v65i5.1180.

DOI:10.4212/cjhp.v65i5.1180
PMID:23129871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3477840/
Abstract
摘要

相似文献

1
Should direct thrombin inhibitors replace warfarin for prophylaxis of thromboembolism in canadians with atrial fibrillation?对于加拿大房颤患者，直接凝血酶抑制剂是否应取代华法林用于预防血栓栓塞？
Can J Hosp Pharm. 2012 Sep;65(5):401-5. doi: 10.4212/cjhp.v65i5.1180.
2
Alternatives to warfarin for thromboembolism prophylaxis in nonrheumatic atrial fibrillation.非风湿性心房颤动患者预防血栓栓塞的华法林替代药物
J Interv Card Electrophysiol. 2004;10 Suppl 1:33-44. doi: 10.1023/B:JICE.0000011344.01006.a1.
3
Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?直接凝血酶抑制剂会取代华法林用于预防房颤的栓塞事件吗？
Curr Opin Cardiol. 2004 Jan;19(1):58-63. doi: 10.1097/00001573-200401000-00012.
4
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].[2011年血栓栓塞预防：华法林是否正在衰落？]
G Ital Cardiol (Rome). 2011 Sep;12(9):556-65. doi: 10.1714/926.10169.
5
[Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].[希美加群用于心房颤动的抗栓治疗：它能替代华法林吗？]
Anadolu Kardiyol Derg. 2007 Mar;7(1):54-8.
6
Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation.直接凝血酶抑制剂：心房颤动血栓预防管理中即将出现的新型抗栓药物。
Postgrad Med J. 2005 Jun;81(956):370-5. doi: 10.1136/pgmj.2004.024521.
7
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.与华法林相比，直接口服Xa因子抑制剂在病态肥胖患者中的疗效和安全性：一项单中心图表数据回顾性分析
Lancet Haematol. 2019 Jul;6(7):e359-e365. doi: 10.1016/S2352-3026(19)30086-9. Epub 2019 May 24.
8
Newer anticoagulants as an alternate to warfarin in atrial fibrillation: a changing paradigm.新型抗凝药物在房颤治疗中替代华法林：观念的转变。
Am J Ther. 2011 Jan;18(1):e1-e11. doi: 10.1097/MJT.0b013e3181d5ae5d.
9
Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis.抗心律失常预防与华法林抗凝治疗预防心房颤动患者血栓栓塞事件的决策分析
Arch Intern Med. 1995 May 8;155(9):913-20.
10
Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis.心房颤动消融术前后口服抗凝药的使用：关于围手术期心房颤动消融术预防血栓栓塞的个体口服抗凝药使用的当前证据综述
J Cardiovasc Electrophysiol. 2014 Dec;25(12):1411-8. doi: 10.1111/jce.12546. Epub 2014 Oct 10.

引用本文的文献

1
Optimal warfarin management can be achieved in all practice settings.
Can J Hosp Pharm. 2013 Mar;66(2):137. doi: 10.4212/cjhp.v66i2.1240.

本文引用的文献

1
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.口服凝血酶和因子 Xa 抑制剂逆转的紧急指导
Am J Hematol. 2012 May;87 Suppl 1:S141-5. doi: 10.1002/ajh.23202. Epub 2012 Apr 4.
2
Determination of rivaroxaban in human plasma samples.测定人血浆样本中的利伐沙班。
Semin Thromb Hemost. 2012 Mar;38(2):178-84. doi: 10.1055/s-0032-1301415. Epub 2012 Feb 17.
3
Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.重组凝血因子VIIa用于预防和治疗非血友病患者的出血。
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD005011. doi: 10.1002/14651858.CD005011.pub4.
4
Human recombinant activated protein C for severe sepsis.用于严重脓毒症的人重组活化蛋白C
Cochrane Database Syst Rev. 2012 Mar 14(3):CD004388. doi: 10.1002/14651858.CD004388.pub5.
5
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.达比加群与急性冠脉事件高风险相关：非劣效性随机对照试验的荟萃分析
Arch Intern Med. 2012 Mar 12;172(5):397-402. doi: 10.1001/archinternmed.2011.1666. Epub 2012 Jan 9.
6
Apixaban versus warfarin in patients with atrial fibrillation.阿哌沙班与华法林用于房颤患者。
N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.
7
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.利伐沙班与华法林用于非瓣膜性心房颤动。
N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.
8
Prothrombin complex concentrate for critical bleeding.用于严重出血的凝血酶原复合物浓缩物。
Ann Pharmacother. 2011 Jul;45(7-8):990-9. doi: 10.1345/aph.1Q096. Epub 2011 Jul 5.
9
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.与华法林相比，达比加群酯在老年和年轻房颤患者中使用 2 剂的出血风险：随机长期抗凝治疗评估（RE-LY）试验分析。
Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16.
10
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.直接因子 Xa 抑制剂的临床实验室检测：抗 Xa 测定优于凝血酶原时间测定。
Thromb Haemost. 2010 Dec;104(6):1263-71. doi: 10.1160/TH10-05-0328. Epub 2010 Oct 26.